Search Results 111-120 of 13183 for Tyrosine
Patients with ALK aberrant tumors (ALK tyrosine kinase mutation or ALK amplification) will be non-randomly assigned to receive crizotinib added to current COG ...
Cutaneous B-cell lymphoma. Displaying 5 studies. A Study Of Tyrosine Kinase Inhibitor ICP-022 In Patients With R/r B-Cell Malignancies Scottsdale/Phoenix, AZ ...
... tyrosine kinase inhibitor (TKI) targeting ALK or who have had prior exposure to crizotinib. Participation eligibility. Participant eligibility includes age ...
Participants who have previously received a covalently-binding Bruton´s tyrosine kinase (BTK) inhibitor (BTKi) in any line of therapy must have received ...
Recent developments or emerging therapies. Bruton's tyrosine kinase (BTK) inhibitor is a therapy being studied in relapsing-remitting multiple sclerosis and ...
Erlotinib (Tarceva) is a human EGFR type 1 tyrosine kinase inhibitor and offers greater survival benefit to EGFR positive patients. This study will assist ...
* Prior treatment with a vascular endothelial growth factor receptor (VEGFR) -targeting tyrosine kinase inhibitor or a mammalian target of rapamycin (mTOR) ...
This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed ...
(Peak) A Phase 3 Randomized Trial Of CGT9486+Sunitinib Vs. Sunitinib In Subjects With Gastrointestinal Stromal Tumors · 1. Prior treatment with < 2 Tyrosine ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Mayo Clinic researchers drive discoveries that improve detection, diagnosis and treatment. Your quick message to them means so much.